[{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Moberg Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Moberg Pharma \/ Moberg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Moberg Pharma"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Dermatology","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Dermatology","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Allderma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Allderma","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Allderma"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Nice & Green","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Nice & Green"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Padagis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Padagis","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Padagis"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Undisclosed","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"CAS 75885-58-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K40a","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MOB015","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Moberg Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
